Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the ...

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Federal funding cuts to vaccine research have impacted scientists nationwide — and some of those cuts hit close to home.

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand declines.

Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

Moderna, Inc. (NASDAQ:MRNA) ranks among the best mid-cap stocks with huge upside potential. Moderna, Inc. (NASDAQ:MRNA) reported on August 27 that the US Food and Drug Administration had granted ...

Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...